Has Orthovita's Fight Finally Ended?

Orthovita had spent the past eight years building up a small commercial pipeline while it ran its flagship bone augmentation material Cortoss through years of a demanding clinical trial. But two months after the FDA approved the product, the company had to clear another unforeseen hurdle: two controversial clinical trials.

By Tom Salemi

Antony Koblish didn't flinch. The CEO of Orthovita Inc. was laying out his complaints about the results of two...

More from Archive

More from In Vivo